financetom
Business
financetom
/
Business
/
Measures by Colombia stock exchange may allow it to stay in JPMorgan index -president
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Measures by Colombia stock exchange may allow it to stay in JPMorgan index -president
Apr 29, 2024 7:19 AM

BOGOTA, April 29 (Reuters) - Measures adopted by the

Colombian stock exchange and securities issuers to improve

liquidity could be enough for the country to hold onto its

"emerging market" classification and stay in a key JPMorgan ( JPM )

index, but more progress is needed, the stock exchange's

president said.

Last year JPMorgan ( JPM ) warned Colombia could be excluded from

its MSCI emerging markets index and be downgraded to a frontier

market due to declining liquidity.

The warning sparked a sharp drop in share prices across the

stock exchange as a downgrade would drive away foreign investors

guided by the bank's indexes.

Just three Colombian stocks are included in JPMorgan's ( JPM ) MSCI

index; Bancolombia, Bancolombia Preferential and energy

conglomerate ISA.

The stock exchange has cut costs for issuing new shares,

while companies have hired liquidity providers to promote them,

among other measures, in a combined effort to boost liquidity,

Colombian stock exchange chief executive Andres Restrepo said.

"From our figures, we don't think the downgrade risk will

materialize," Restrepo told Reuters late on Friday. "The

performance of the three stocks that form part of the MSCI

Emerging index has recovered."

In March, Davivienda, Colombia's third-largest bank, carried

out a share issue for $183.4 million, while Spanish bank BBVA's

Colombian unit said in mid-April that it was preparing a share

issue worth 220 million euros.

The next step will be to promote including other companies

into JPMorgan's ( JPM ) MSCI emerging markets index, which will require

more share issues, said Restrepo, who has held the job since

February.

Cementos Argos could be a candidate following a

decision to convert its preferential shares into common shares,

Restrepo said, adding that Colombia's majority state-owned oil

company Ecopetrol could return to the index after it

was pushed out at the end of 2022.

"Ecopetrol could very quickly enter the index with a

decision I understand is no small thing, but which is to

increase its float by selling no more than 3% (of its shares),"

Restrepo said.

Currently, 11.5% of Ecopetrol's shares are traded on the

stock market, while 88.5% is owned by the Colombian state.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $2,263,942, According to a Recent SEC Filing
Jan 13, 2025
03:22 AM EST, 01/13/2025 (MT Newswires) -- Rami Elghandour, Director, President, Chief Executive Officer and Chairman of the Board, on January 07, 2025, sold 30,311 shares in Arcellx ( ACLX ) for $2,263,942. Following the Form 4 filing with the SEC, Elghandour has control over a total of 117,275 shares of the company, with 117,275 shares held directly. SEC Filing:...
Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing
Arcellx Insider Sold Shares Worth $1,355,024, According to a Recent SEC Filing
Jan 13, 2025
03:22 AM EST, 01/13/2025 (MT Newswires) -- Michelle Gilson, Chief Financial Officer, on January 07, 2025, sold 18,009 shares in Arcellx ( ACLX ) for $1,355,024. Following the Form 4 filing with the SEC, Gilson has control over a total of 9,582 shares of the company, with 9,582 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1786205/000141588925001345/xslF345X05/form4-01112025_020131.xml ...
GSK to Acquire Oncology Firm IDRx for Up to $1.15 Billion
GSK to Acquire Oncology Firm IDRx for Up to $1.15 Billion
Jan 13, 2025
03:21 AM EST, 01/13/2025 (MT Newswires) -- GSK (GSK) has agreed to acquire oncology company IDRx for up to $1.15 billion, the companies said Monday. The consideration includes $1 billion in an upfront payment, and up to $150 million in potential regulatory-based milestone payments. GSK will also be responsible for milestone and royalty payments owed to Merck KGaA related to...
Bezos' Blue Origin delays New Glenn debut launch
Bezos' Blue Origin delays New Glenn debut launch
Jan 13, 2025
WASHINGTON, Jan 13 (Reuters) - Jeff Bezos' Blue Origin called off the launch of its New Glenn rocket after a few anomalies during the mission countdown on Monday, postponing by at least a day an inaugural attempt to reach orbit and compete with SpaceX in the satellite launch market. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved